Boston Scientific (NYSE:BSX) had its price objective raised by equities research analysts at Argus from $41.00 to $43.00 in a research note issued to investors on Friday. The brokerage presently has a “buy” rating on the medical equipment provider’s stock. Argus’ price target points to a potential upside of 20.01% from the stock’s current price.

BSX has been the subject of a number of other reports. BTIG Research reissued a “buy” rating and set a $45.00 price objective on shares of Boston Scientific in a research note on Tuesday, October 16th. Oppenheimer set a $38.00 price objective on shares of Boston Scientific and gave the stock a “hold” rating in a research note on Wednesday. Canaccord Genuity raised their price objective on shares of Boston Scientific from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday. Royal Bank of Canada raised their price objective on shares of Boston Scientific to $36.00 and gave the stock a “top pick” rating in a research note on Monday, July 23rd. Finally, Morgan Stanley raised their target price on shares of Boston Scientific from $38.00 to $48.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have assigned a buy rating and three have issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $39.00.

Shares of BSX opened at $35.83 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.83 and a quick ratio of 0.60. Boston Scientific has a 1-year low of $24.54 and a 1-year high of $39.44. The company has a market cap of $49.55 billion, a PE ratio of 25.06, a price-to-earnings-growth ratio of 2.48 and a beta of 0.59.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, October 24th. The medical equipment provider reported $0.35 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.34 by $0.01. Boston Scientific had a net margin of 6.93% and a return on equity of 27.38%. The business had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.40 billion. During the same period last year, the company posted $0.31 EPS. The company’s revenue was up 7.7% on a year-over-year basis. As a group, sell-side analysts expect that Boston Scientific will post 1.39 earnings per share for the current fiscal year.

In other Boston Scientific news, Chairman Michael F. Mahoney sold 116,666 shares of Boston Scientific stock in a transaction on Monday, October 1st. The shares were sold at an average price of $38.80, for a total value of $4,526,640.80. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP David A. Pierce sold 5,000 shares of Boston Scientific stock in a transaction on Wednesday, August 1st. The shares were sold at an average price of $33.66, for a total transaction of $168,300.00. Following the completion of the transaction, the executive vice president now owns 29,201 shares in the company, valued at approximately $982,905.66. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 295,834 shares of company stock worth $11,038,468. 0.73% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the business. IMA Wealth Inc. boosted its holdings in shares of Boston Scientific by 1.1% in the 3rd quarter. IMA Wealth Inc. now owns 117,815 shares of the medical equipment provider’s stock valued at $4,536,000 after purchasing an additional 1,330 shares during the last quarter. First American Trust FSB boosted its holdings in shares of Boston Scientific by 1.3% in the 3rd quarter. First American Trust FSB now owns 113,375 shares of the medical equipment provider’s stock valued at $4,365,000 after purchasing an additional 1,470 shares during the last quarter. Cubist Systematic Strategies LLC boosted its holdings in shares of Boston Scientific by 3.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 51,105 shares of the medical equipment provider’s stock valued at $1,671,000 after purchasing an additional 1,547 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its holdings in shares of Boston Scientific by 4.0% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 39,979 shares of the medical equipment provider’s stock valued at $1,537,000 after purchasing an additional 1,555 shares during the last quarter. Finally, Captrust Financial Advisors boosted its holdings in shares of Boston Scientific by 103.8% in the 2nd quarter. Captrust Financial Advisors now owns 3,129 shares of the medical equipment provider’s stock valued at $102,000 after purchasing an additional 1,594 shares during the last quarter. Institutional investors own 91.02% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Featured Story: Asset Allocation, Balancing Your Investments

Analyst Recommendations for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.